Is PSMA PET the Solution for MRI-Occult Prostate Cancer?

Is PSMA PET the Solution for MRI-Occult Prostate Cancer?

Multiparametric MRI has transformed the diagnostic pathway for suspected prostate cancer. However, clinicians still find that its negative predictive value declines in higher-risk populations. Up to 30% of men with negative MRI results may still harbor clinically significant disease. Specifically, PSMA PET in prostate cancer has emerged as a promising complementary modality to address these critical gaps.

Diagnostic Value of PSMA PET in Prostate Cancer

Prospective studies such as PRIMARY and PEDAL demonstrate significant diagnostic benefits. Specifically, PSMA PET/CT detects many aggressive cancers that traditional MRI often misses. Furthermore, it achieves high sensitivity and an excellent negative predictive value. This performance is particularly helpful for men with indeterminate MRI results. Therefore, integrating this technology could reduce unnecessary biopsies in selected patients. Moreover, it ensures that surgeons identify significant disease much earlier. Consequently, patients receive more accurate risk stratification before undergoing invasive procedures.

Standardizing Reports with the PRIMARY Score

Standardization remains a critical hurdle for widespread clinical adoption. Consequently, experts developed the PRIMARY score to create a structured reporting system for scans. This system improves comparability across different medical studies and centers. Moreover, it allows radiologists to provide more reliable and consistent interpretations. Thus, clinicians can trust these findings when making vital treatment decisions. High inter-reader agreement suggests that this scoring system is highly reproducible in routine practice.

Evaluating Biological Relevance and Costs

Despite these clear benefits, some uncertainties still remain for physicians. For instance, we must understand the biological significance of PSMA-positive lesions that appear MRI-negative. Researchers are still investigating whether all these lesions represent clinically meaningful disease. Additionally, hospitals must consider the cost-effectiveness of routine PSMA scans. Future integration depends on proving its value in large-scale clinical pathways. Finally, careful patient selection will ensure the best outcomes for Indian men facing a prostate cancer diagnosis.

Frequently Asked Questions

Q1: Can PSMA PET/CT reduce the number of unnecessary biopsies?

Yes, the PRIMARY2 trial showed that PSMA PET/CT could help nearly half of men avoid unnecessary biopsies when the scan remains negative.

Q2: What is the PRIMARY score in prostate imaging?

The PRIMARY score is a standardized reporting system designed to improve the interpretation and comparability of PSMA PET/CT results across different clinical settings.

Q3: Should PSMA PET replace multiparametric MRI?

Currently, PSMA PET is viewed as a complementary tool rather than a replacement. It provides additional sensitivity when MRI results are indeterminate or negative despite clinical suspicion.

References

1. Wagner T et al. PSMA PET: the answer to MRI-occult prostate cancer… or another mirage? Eur Radiol. 2026 Apr 30. doi: 10.1007/s00330-026-12596-3. PMID: 42059962.
2. Emmett L et al. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022 Nov;63(11):1644-1650.
3. Buteau J et al. PRIMARY2: PSMA-PET/CT can safely reduce prostate biopsies in men with equivocal MRI. Presented at EAU 2026 Annual Congress.